Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder
| Autor: | Lynette M. Smith, David Driscoll, Subhash C. Bhatia, Sriram Ramaswamy, Frederick Petty |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Population Atypical antipsychotic behavioral disciplines and activities Article law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law mental disorders Medicine Ziprasidone education Psychiatry Pharmacology lcsh:R5-920 education.field_of_study Post-traumatic stress disorder business.industry Traumatic stress Hamilton Rating Scale for Depression PTSD General Medicine medicine.disease 030227 psychiatry Clinical Global Impression Major depressive disorder Geodon lcsh:Medicine (General) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Contemporary Clinical Trials Communications, Vol 2, Iss C, Pp 1-5 (2016) Contemporary Clinical Trials Communications |
| ISSN: | 2451-8654 |
| DOI: | 10.1016/j.conctc.2015.12.003 |
| Popis: | Background Post-traumatic stress disorder (PTSD) is a chronic anxiety disorder that is often difficult to treat. Patients suffering from PTSD often fail to respond to antidepressants and may have a high incidence of positive symptoms of psychosis, though antipsychotic medications have been minimally studied in this population. The aim of this study was to assess the impact of the atypical antipsychotic ziprasidone (Geodon) on PTSD symptom clusters, as well as comorbid major depressive disorder. To our knowledge, this is the first completed randomized controlled trial investigating the potential efficacy and tolerability of ziprasidone in patients with chronic PTSD. Methods We conducted a 9-week prospective, randomized, double-blind, placebo-controlled trial of ziprasidone in 30 patients diagnosed with PTSD and comorbid depression. After screening and randomization, patients completed nine weekly study visits at which treatment safety and efficacy were evaluated. Primary measures of efficacy included total and subscale scores from the Clinician-Administered PTSD Scale (CAPS), while the Hamilton Rating Scale for Depression (HAM-D), Hamilton Anxiety Scale (HAM-A), Clinical Global Impression (CGI), and Treatment Outcome PTSD Scale (TOP-8) were implemented as secondary efficacy measures. Results We observed no significant effect of treatment on reduction of PTSD or depression symptoms from pre- to post-treatment. Conclusions Our findings suggest that ziprasidone treatment may not significantly improve symptoms of PTSD or comorbid depression, though further study is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|